| 28.51 -0.64 (-2.2%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.33 |
1-year : | 40.1 |
| Resists | First : | 29.39 |
Second : | 34.33 |
| Pivot price | 24.56 |
|||
| Supports | First : | 24.24 |
Second : | 21.05 |
| MAs | MA(5) : | 25.73 |
MA(20) : | 24.14 |
| MA(100) : | 16.83 |
MA(250) : | 12.54 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 91.7 |
D(3) : | 74.6 |
| RSI | RSI(14): 63.4  |
|||
| 52-week | High : | 40.36 | Low : | 4.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CAPR ] has closed Bollinger Bands are 3.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.42 - 29.57 | 29.57 - 29.68 |
| Low: | 27.2 - 27.36 | 27.36 - 27.47 |
| Close: | 28.26 - 28.52 | 28.52 - 28.72 |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Sat, 21 Feb 2026
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unveiling a 74% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Fri, 20 Feb 2026
CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On - Stocktwits
Sat, 07 Feb 2026
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving Average - Time to Sell? - MarketBeat
Fri, 30 Jan 2026
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sat, 10 Jan 2026
Capricor Therapeutics: A High Risk/High Reward Name - Seeking Alpha
Thu, 18 Dec 2025
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 16.7 (%) |
| Held by Institutions | 40.6 (%) |
| Shares Short | 5,110 (K) |
| Shares Short P.Month | 5,030 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.83 |
| Profit Margin | 0 % |
| Operating Margin | -778.8 % |
| Return on Assets (ttm) | -49.4 % |
| Return on Equity (ttm) | -107.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.2 |
| Sales Per Share | 0.2 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -16.3 |
| PEG Ratio | 0 |
| Price to Book value | 15.57 |
| Price to Sales | 139.34 |
| Price to Cash Flow | -25.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|